v3.26.3
Subsequent Events
9 Months Ended
Sep. 30, 2026
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
On October 28, 2026, Sanofi dosed the fifth patient in its Phase 3 influenza-COVID-19 combination vaccine trial in the European Union, utilizing the Company’s COVID-19 component. Dosing of the fifth patient has triggered a $125.0 million milestone payment from Sanofi under the Company’s CLA with Sanofi. The Company anticipates receipt of payment by the first quarter of 2027.